Download PDF
Horm Metab Res 2020; 52(08): 614-620
DOI: 10.1055/a-1110-7251
Review

Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms

Marina Tsoli
1   1st Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Krystallenia Alexandraki
1   1st Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Christos Xanthopoulos
1   1st Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
,
Eva Kassi
1   1st Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
2   Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece
,
Gregory Kaltsas
1   1st Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Neuroendocrine neoplasms (NENs) are rare tumours that arise mainly in the gastrointestinal or pulmonary system. Most NENs are well-differentiated and may obtain prolonged survival besides the presence of metastatic disease; however, a subset (poorly differentiated NENs) may display a truly aggressive behaviour exhibiting a poor prognosis. The recently developed classification systems along with advances in functional imaging have helped stratify patients to the administration of appropriate therapeutic options. Surgery is the mainstay of treatment of NENs, but in recent decades there has been a considerable evolution of medical treatments that are used for locally advanced or metastatic disease not amenable to surgical resection. Long acting somatostatin analogues are the main therapeutic modality for patients with functioning and well-differentiated low grade NENs exhibiting symptomatic control and mainly stabilisation of tumour growth. Other systemic treatments include chemotherapy, molecular targeted agents, interferon-α, peptide receptor radionuclide therapy (PRRT), and immunotherapy. In addition, new agents such as telotristat may be used for the control of symptoms of carcinoid syndrome. The choice and/or sequence of therapeutic agents should be individualized according to tumour origin and differentiation, disease burden, presence of clinical symptoms and patients’ performance status in the context of a multidisciplinary approach. Recent advances in the molecular pathogenesis of NENs set the field for a more personalised treatment approach.

Key words

neuroendocrine tumour - somatostatin analogues - radionuclides - targeted treatment - carcinoid syndrome


Publication History

Received: 01 July 2019

Accepted: 22 January 2020

Article published online:
27 February 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Modlin IM, Oberg K, Chung DC. et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72
    Google Scholar
  • 2 Huguet I, Grossman AB, O’Toole D. Changes in the Epidemiology of Neuroendocrine Tumours. Neuroendocrinology 2017; 104: 105-111
    Google Scholar
  • 3 Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072
    Google Scholar
  • 4 Crona J, Norlen O, Antonodimitrakis P. et al. Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours. J Clin Endocrinol Metab 2016; 101: 445-452
    Google Scholar
  • 5 Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511
    Google Scholar
  • 6 Kloppel G, Rindi G, Perren A. et al. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch 2010; 456: 595-597
    Google Scholar
  • 7 Basturk O, Yang Z, Tang LH. et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39: 683-690
    Google Scholar
  • 8 Klimstra DS, Kloppell G, La Rosa S. et al. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed.), International Agency for Research on Cancer. Lyon 2019; 16
    Google Scholar
  • 9 Tsoli M, Chatzellis E, Koumarianou A. et al. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab 2019; 10: 2042018818804698
    Google Scholar
  • 10 Kaderli RM, Spanjol M, Kollar A. et al. Therapeutic options for neuroendocrine tumors: A systematic review and network meta-analysis. JAMA Oncol 2019; 5: 480-489
    Google Scholar
  • 11 Laskaratos FM, Caplin M. Treatment challenges in and outside a network setting: Gastrointestinal neuroendocrine tumours. Eur J Surg Oncol 2019; 45: 52-59
    Google Scholar
  • 12 Oberg KE, Reubi JC, Kwekkeboom DJ. et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010; 139: 742-53 753 e1
    Google Scholar
  • 13 Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol 2008; 286: 238-250
    Google Scholar
  • 14 de Herder WW, Hofland LJ, van der Lely AJ. et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003; 10: 451-458
    Google Scholar
  • 15 Chan JA, Kulke MH. Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep 2009; 11: 193-199
    Google Scholar
  • 16 Modlin IM, Pavel M, Kidd M. et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-188
    Google Scholar
  • 17 Merola E, Panzuto F, Delle Fave G. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget 2017; 8: 46624-46634
    Google Scholar
  • 18 Rinke A, Muller HH, Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663
    Google Scholar
  • 19 Caplin ME, Pavel M, Cwikla J. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 224-233
    Google Scholar
  • 20 Strosberg JR, Benson AB, Huynh L. et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist 2014; 19: 930-936
    Google Scholar
  • 21 Pavel M, Valle JW, Eriksson B. et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: Systemic therapy – biotherapy and novel targeted agents. Neuroendocrinology 2017; 105: 266-280
    Google Scholar
  • 22 Cives M, Kunz PL, Morse B. et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer 2015; 22: 1-9
    Google Scholar
  • 23 Wolin EM, Jarzab B, Eriksson B. et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 2015; 9: 5075-5086
    Google Scholar
  • 24 Alexandraki KI, Daskalakis K, Tsoli M. et al. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends Endocrinol Metab 2019; pii: S1043-2760(19)30225-5 DOI: 10.1016/j.tem.2019.11.003 [Epub ahead of print].
    Google Scholar
  • 25 Yao JC, Phan A, Chang D. et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318
    Google Scholar
  • 26 Pavel ME, Hainsworth JD, Baudin E. et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378(9808): 2005-2012
    Google Scholar
  • 27 Yao JC, Shah MH, Ito T. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523
    Google Scholar
  • 28 Yao JC, Pavel M, Lombard-Bohas C. et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol 2016; 34: 3906-3913
    Google Scholar
  • 29 Pavel M, O'Toole D, Costa F. et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016; 103: 172-185
    Google Scholar
  • 30 Raymond E, Daham L, Raoul JL. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513
    Google Scholar
  • 31 Phan AT, Halperin DM, Chan JA. et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 2015; 16: 695-703
    Google Scholar
  • 32 Strosberg JR, Cives M, Hwang J. et al. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer 2016; 23: 411-418
    Google Scholar
  • 33 Auernhammer CJ, Spitzweg C, Angele MK. et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol 2018; 6: 404-415
    Google Scholar
  • 34 Angelousi A, Kamp K, Kaltsatou M. et al. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments. Neuroendocrinology 2017; 105: 394-402
    Google Scholar
  • 35 Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189-1194
    Google Scholar
  • 36 Moertel CG, Lefkopoulo M, Lipsitz S. et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-523
    Google Scholar
  • 37 Dilz LM, Denecke T, Steffen IG. et al. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 2015; 51: 1253-1262
    Google Scholar
  • 38 Heetfeld M., Chougnet CN, Olsen IH. et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; 22: 657-664
    Google Scholar
  • 39 Wong MH, Chan D, Lee A. et al. Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PLoS One 2016; 11: e0158140
    Google Scholar
  • 40 Angelousi A, Kaltsas G, Koumarianou A. et al. Chemotherapy in NETs: When and how. Rev Endocr Metab Disord 2017; 18: 485-497
    Google Scholar
  • 41 Strosberg JR, Fine RL, Choi J. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275
    Google Scholar
  • 42 Chatzellis E, Angelousi A, Daskalakis K. et al. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms. Neuroendocrinology 2019; 109: 333-345
    Google Scholar
  • 43 Garcia-Carbonero R, Rinke A, Valle JW. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. Neuroendocrinology 2017; 105: 281-294
    Google Scholar
  • 44 Ahlman H, Nilsson O, McNikol AM. et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008; 87: 40-46
    Google Scholar
  • 45 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376: 125-135
    Google Scholar
  • 46 Strosberg J, Wolin E, Chasen B. et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 2018; 36: 2578-2584
    Google Scholar
  • 47 Severi S, Nanni O, Bodei L. et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40: 881-888
    Google Scholar
  • 48 Sansovini M, Severi S, Ianniello A. et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE. Eur J Nucl Med Mol Imaging 2017; 44: 490-499
    Google Scholar
  • 49 Claringbold PG, Brayshaw PA, Price RA. et al. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011; 38: 302-311
    Google Scholar
  • 50 Kashyap R, Hofman MS, Michael M. et al. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2015; 42: 176-185
    Google Scholar
  • 51 Cives M, Strosberg J. Radionuclide Therapy for Neuroendocrine Tumors. Curr Oncol Rep 2017; 19: 9
    Google Scholar
  • 52 Bodei L, Kidd M, Paganelli G. et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015; 42: 5-19
    Google Scholar
  • 53 Baum RP, Kulkarni H, Singh A. et al. Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget 2018; 9: 16932-16950
    Google Scholar
  • 54 Oberg K. Biotherapies for GEP-NETs. Best Pract Res Clin Gastroenterol 2012; 26: 833-841
    Google Scholar
  • 55 Oberg K, Norheim I, Lind E. et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep 1986; 70: 1297-1304
    Google Scholar
  • 56 Faiss S, Pape UF, Bohmig M. et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696
    Google Scholar
  • 57 Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000; 62 (Suppl 1) 92-97
    Google Scholar
  • 58 Niederle B, Pape UF, Costa F. et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016; 103: 125-138
    Google Scholar
  • 59 Chauhan A, Horn M, Magee G. et al. Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature. Oncotarget 2018; 9: 8801-8809
    Google Scholar
  • 60 Kaltsas G, Caplin M, Davies P. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology 2017; 105: 245-254
    Google Scholar
  • 61 Dimitriadis GK, Weickert MO, Randeva HS. et al. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2016; 23: R423-R436
    Google Scholar
  • 62 Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol 2012; 26: 737-753
    Google Scholar
  • 63 Hofland J, Herrera Martinez AD, Zandee WT. et al. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer 2019; pii: ERC-18-0495.R1 DOI: 10.1530/ERC-18-0495 [Epub ahead of print].
    Google Scholar
  • 64 Kulke MH, Horsch D, Caplin ME. et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol 2017; 35: 14-23
    Google Scholar
  • 65 Pavel M, Horsch D, Caplin M. et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab 2015; 100: 1511-1519
    Google Scholar
  • 66 Weickert MO, Kaltsas G, Horsch D. et al. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clin Ther 2018; 40: 952-962
    Google Scholar
  • 67 de Herder WW, Schaik E, Kwekkeboom D. et al. New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf) 2011; 75: 277-284
    Google Scholar
  • 68 Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009; 360: 195-197
    Google Scholar
  • 69 Novotny J, Janku F, Mares P. et al. Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. Support Care Cancer 2005; 13: 760-762
    Google Scholar
  • 70 Jensen RT, Gadiot G, Brandi ML. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119
    Google Scholar
  • 71 Gaudenzi G, Dicitore A, Carra S. et al. Management of Endocrine Disease: Precision medicine in neuroendocrine neoplasms: an update on current management and future perspectives. Eur J Endocrinol 2019; 181: R1-R10
    Google Scholar
  • 72 Neychev V, Steinberg SM, Cottle-Delisle C. et al. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open 2015; 5: 008248
    Google Scholar
  • 73 Malczewska A, Kos-Kudla B, Kidd M. et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2019; 65: 18-29
    Google Scholar
  • 74 Faggiano A, Di Maio S, Mocerino C. et al. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine 2019; 66: 417-424
    Google Scholar